Vancomycin combined with piperacillin/tazobactam increases the risk of acute kidney injury compared with vancomycin plus other anti-pseudomonal beta-lactams: a systematic review and network meta-analysis
The DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index.
Abstract
Objective: To explore whether vancomycin plus piperacillin/tazobactam actually increases nephrotoxicity compared with other anti-pseudomonal beta-lactams (BLs). Methods: PubMed, Embase, Web of Science, Cochrane, CNKI, Wanfang and VIP were searched from inception to October 2023. The primary outcomes were acute kidney injury (AKI) as defined as acute increase in serum creatinine of 0.3 mg/dL or 50% and severe Stage 2–3 AKI. Results: We included 70 studies (76 638 patients). Network meta-analysis indicated that vancomycin plus piperacillin/tazobactam was associated with significantly higher AKI risk than vancomycin plus cefepime (OR 2.55, 95% CI 2–3.28), vancomycin plus meropenem (OR 2.26, 95% CI 1.71–3.02) and vancomycin plus other uncommonly used BLs (OR 2.47, 95% CI 1.87–3.29). Also, vancomycin + piperacillin/tazobactam was associated with significantly higher Stage 2–3 AKI risk than vancomycin + cefepime (OR 2.22, 95% CI 1.34–3.62), vancomycin + meropenem (OR1.96, 95% CI 1.22–3.25) and vancomycin + uncommonly used BLs (OR 2.81, 95% CI 1.66–4.91). Vancomycin plus piperacillin/tazobactam did not result in a significant difference in the incidence of receiving dialysis treatment, mortality, length of stay and time to AKI. Subgroup analyses of studies conducting propensity score matching demonstrated vancomycin + piperacillin/tazobactam was associated with significantly higher AKI rates than vancomycin + cefepime (OR 2.19, 95% CI 1.38–3.47) and vancomycin + meropenem (OR 1.38, 95% CI. 1.18–1.60). Subgroup analysis of critically ill patients and children indicated that vancomycin + piperacillin/tazobactam was associated with significantly higher AKI rates. Conclusions: Vancomycin + piperacillin/tazobactam significantly increased the risk of AKI and severe Stage 2–3 AKI compared with vancomycin plus other BLs. More prospective studies are needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Randomized and observational evidence has focused attention on renal outcomes during broad beta-lactam and vancomycin-containing therapy (22, 23).”
From Day-4 antipseudomonal and anti-MRSA de-escalation was not associated with higher mortality in critically ill patients with sepsis (2026) · cites this paper as [22]
Citations
Cites
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329
Austin, P. C. (2011) · Multivariate Behavioral Research · doi:10.1080/00273171.2011.568786 · Cited by 12,242
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269
KDIGO Clinical Practice Guidelines for Acute Kidney Injury
Khwaja, A. (2012) · Nephron Clinical Practice · doi:10.1159/000339789 · Cited by 8,014
Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury
Mehta, R. L., Kellum, J. A., Shah, S. V., Molitoris, B. A., Ronco, C., Warnock, D. G., Levin, A., & the Acute Kidney Injury Network (2007) · Critical Care · doi:10.1186/cc5713 · Cited by 7,048
Bellomo, R., Ronco, C., Kellum, J. A., Mehta, R. L., Palevsky, P., & workgroup, T. A. (2004) · Critical Care · doi:10.1186/cc2872 · Cited by 6,781
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Rybak, M. J., Le, J., Lodise, T. P., Levine, D. P., Bradley, J. S., Liu, C., Mueller, B. A., Pai, M. P., Wong-Beringer, A., Rotschafer, J. C., et al. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa036 · Cited by 1,202
Acute kidney injury in China: a cross-sectional survey
Yang, L., Xing, G., Wang, L., Wu, Y., Li, S., Xu, G., He, Q., Chen, J., Chen, M., Liu, X., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00344-x · Cited by 469
Self-citationThe Nephrotoxicity of Vancomycin
Filippone, E., Kraft, W., & Farber, J. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.726 · Cited by 416
Research works printed but not linked: 6
- Coutinho Cabral, 2021, Acute kidney injury in the concomitant treatment of vancomycin with piperacillin/tazobactam, Rev OFIL, 31, 45, 10.4321/s1699-714x20210001000011 · doi:10.4321/s1699-714x20210001000011
- Gao, 2015, Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized children with or without concomitant piperacillin-tazobactam, Fudan Univ J Med Sci, 42, 743, 10.3969/j.issn.1672-8467.2015.06.009 · doi:10.3969/j.issn.1672-8467.2015.06.009
- Wen, 2021, The effects of vancomycin monotherapy and combined beta-lactam therapy on occurrence and prognosis of acute kidney injury in patients with sepsis, Tianjin Yiyao, 49, 36, 10.11958/20201821 · doi:10.11958/20201821
- Xu, 2021, Acute kidney injury in critically ill patients receiving vancomycin and concomitant beta-lactam antibiotics, Zhongnan Yaoxue, 19, 2699, 10.7539/j.issn.1672-2981.2021.12.043 · doi:10.7539/j.issn.1672-2981.2021.12.043
- Wang, 2023, Comparison of acute kidney injury risk associated with vancomycin and concomitant piperacillin-tazobactam or carbapenem, Chin J Hosp Pharm, 43, 1851, 10.13286/j.1001-5213.2023.16.14 · doi:10.13286/j.1001-5213.2023.16.14
- Chu, 2023, Effect of vancomycin combined with piperacillin tazobactam on acute kidney injury in patient with sepsis, Northwest Pharm J, 38, 135, 10.3969/j.issn.1004-2407.2023.05.024 · doi:10.3969/j.issn.1004-2407.2023.05.024
Cited by
Karimzadeh, I., Kane‐Gill, S. L., & Ma, B. (2025) · Antibiotics · doi:10.3390/antibiotics14111138 · Cited by 7
Prolonged Bacillus cereus bacteremia: case report and literature review
Hirao, Y., Morioka, H., Agata, T., Iimura, M., Taki, S., & Yagi, T. (2025) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2025.102736 · Cited by 6
Caragea, M.-E., Caragea, D. C., Assani, M.-Z., Siloşi, I., Boldeanu, M. V., Radu, L., Boldeanu, L., & Vere, C. C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114999 · Cited by 3
Ishigo, T., Suzuki, Y., Ibe, Y., Fujii, S., Fukudo, M., Yoshida, H., Tanaka, H., Fujihara, H., Yamaguchi, F., Ebihara, F., et al. (2026) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkag012 · Cited by 2
Burad, J. (2026) · Infectious diseases · doi:10.5772/intechopen.1014261 · Cited by 1
Factors Affecting Vancomycin and Piperacillin–Tazobactam-Induced Nephrotoxicity
Day, M. V., Munshi, R., Picard, K., & Malek, A. E. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15135020 · Cited by 1
Chen, S., Zhang, Y., Hou, X., Wang, Y., Zuo, C., Huang, C., Xia, X., Cao, C., Lv, Q., Xm, L., et al. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s618586 · Cited by 1
Self-citationKidney Failure in Cardiogenic Shock
Hanff, T. C., Zweck, E., Burton, J. S., Ramkumar, N., Rali, A. S., & Vorovich, E. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.126.014189 · Cited by 1
Zhang, Y., Liao, G., Song, J., Liao, Y., & Zhang, L. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1924203
Hurley, J. C. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf282
Golbus, A. L., Park, E., Harris, C. E., Quadri, S. S. A., Mukherjee, R., Killic, A., Tedford, R. J., & McMahon, B. A. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-12788-8
Villa, G. G., Ho, C., & Abdelhakiem, A. K. (2026) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxag127
Wang, C., Xia, H., Fu, Y.-P., Shen, N.-N., & Yue-mei, F. U. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1793497
Hu, Q., & Wang, H. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s594482
Werneburg, F., Zeh, A., Gutteck, N., & Delank, K.-S. (2026) · Journal of Bone and Joint Infection · doi:10.5194/jbji-11-343-2026
Ishaqui, A. A., Tripathi, R., Tripathi, P., Alqahtani, S. S., Makeen, H. A., & Orayj, K. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05596-z
Pan, K., Hou, X., Li, J., Zhang, Y., Wang, Y., Zuo, C., Li, R., Ding, X., Lv, Q., & Li, X. Q. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.00821-26
Self-citationRehman, H. S. U., Ahsan, M. Z., & Khalid, S. (2026) · Insights-Journal of Health and Rehabilitation · doi:10.71000/x095v557
James, M., May, K., Dulhunty, J. M., Whitaker, A. S., Brischetto, A., O’Callaghan, K. P., & Yui, N. A. (2026) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr.70097
Qian, E. T., Linck, E. J. G., Spicer, A. B., Buell, K. G., Casey, J. D., Seitz, K. P., Self, W. H., Wang, L., Wright, A., Rice, T. W., et al. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag544
A Gene-Driven Personalized Treatment Strategy for Diabetic Foot UlcersPreprint
Mahendran, M. I. M. S., Gopalakrishnan, V., Saravanan, V., Vaithianathan, R., & Natarajan, V. (2026) · doi:10.22541/authorea.15010641/v1
Bates, B. N., Brown, A., & Landin, K. L. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.00688-6
Metadata
- Authors
- Pan, K., Li, R., Li, Y., Ding, X., Li, X., & Lv, Q.
- Affiliations
- Fudan University (CN)
- Shanghai Medical College of Fudan University (CN)
- Corresponding author
- Pan, Kunming
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2024-11-13
- Volume
- 80
- Issue
- 1
- Pages
- 47-58
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W4404334750
- Cited by
- 16
- References
- 94
- Citations by year
- 2026: 13 · 2025: 3
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Antimicrobial Chemotherapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (82204520)
- China International Medical Foundation (Z-2021-46-2101)
- Chinese Pharmaceutical Association (CPA-Z05-ZC-2023-003)
- Shanghai Pharmaceutical Association ((2023)04)
- Shanghai Municipal Health Commission (202240293, shslczdzk06504)
- Shanghai Hospital Development Center Foundation (SHDC12024632)
- Topics
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- vancomycin, piperacillin-tazobactam, acute kidney injury, nephrotoxicity, cefepime, meropenem, combination antibiotic therapy, critically ill patients, dialysis, mortality, length of hospital stay, propensity score matching, propensity score weighting
- MeSH terms
- Cefepime, Piperacillin, Tazobactam Drug Combination, Meropenem, Anti-Bacterial Agents, Drug Therapy, Combination, Humans, Vancomycin, beta-Lactams, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.